MCID: HMT002
MIFTS: 62

Hematologic Cancer

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Hematologic Cancer

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 38 12 55 15
Hematologic Neoplasm 12 29 6
Hematologic Malignancy 12 15
Hematologic Neoplasms 44 73
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematologic Malignancies 55
Hematopoietic Neoplasms 73
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2531
MeSH 44 D019337
NCIt 50 C27134

Summaries for Hematologic Cancer

Disease Ontology : 12 An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasm, is related to childhood leukemia and bone marrow cancer. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Endometrial cancer. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Related Diseases for Hematologic Cancer

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 347)
# Related Disease Score Top Affiliating Genes
1 childhood leukemia 32.7 ABL1 ETV6 KMT2A RUNX1
2 bone marrow cancer 32.2 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
3 myeloproliferative neoplasm 32.0 ABL1 JAK2 KIT MPL
4 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 31.8 ETV6 FLT3 KIT KMT2A RUNX1
5 8p11 myeloproliferative syndrome 31.7 FLT3 KIT RUNX1
6 lymphoma, non-hodgkin, familial 31.6 CSF2 IL2 IL3 JAK2
7 myeloma, multiple 30.8 CSF2 IL2 JAK2 KIT PVT1
8 myelodysplastic syndrome 30.6 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
9 acute leukemia 30.5 ETV6 FLT3 IL3 JAK2 KIT KMT2A
10 myelofibrosis 30.5 FLT3 IL3 JAK2 KIT MPL
11 aplastic anemia 30.5 CSF2 FLT3 IL2 IL3 MPL
12 myeloid sarcoma 30.5 FLT3 KIT KMT2A
13 acute lymphocytic leukemia 30.4 CSF2 ETV6 IL2 RUNX1 XIST
14 pancytopenia 30.3 CSF2 IL3 MPL
15 leukemia 30.2 ABL1 CSF2 ETV6 FLT3 JAK2 KIT
16 myeloid leukemia 30.2 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
17 leukemia, chronic myeloid 30.2 ABL1 CBL CSF2 ETV6 FLT3 IL3
18 leukemia, acute myeloid 30.2 ABL1 CCDC26 CSF2 ETV6 FLT3 IL2
19 precursor t-cell acute lymphoblastic leukemia 30.2 ABL1 ETV6 FLT3 KMT2A MLLT10 NUP98
20 polycythemia 30.2 IL3 JAK2 MPL
21 polycythemia vera 30.2 ABL1 IL3 JAK2 KIT MPL
22 acute promyelocytic leukemia 30.1 FLT3 IL3 PVT1 RUNX1 WT1
23 leukemia, acute monocytic 30.1 KMT2A MLLT10 NUP98
24 essential thrombocythemia 30.1 ABL1 IL3 JAK2 MPL
25 refractory anemia 30.1 IL3 JAK2 MPL RUNX1
26 diphtheria 30.0 CSF2 IL2 IL3
27 retinitis pigmentosa and erythrocytic microcytosis 30.0 IL3 JAK2
28 leukemia, acute lymphoblastic 30.0 ABL1 ETV6 FLT3 KMT2A RUNX1
29 lymphocytic leukemia 29.9 ETV6 IL2 KMT2A RUNX1
30 central nervous system hematologic cancer 12.4
31 refractory hematologic cancer 12.4
32 myeloproliferative/lymphoproliferative neoplasms, familial 11.8
33 fusariosis 11.3
34 hairy cell leukemia 11.3
35 platelet disorder, familial, with associated myeloid malignancy 11.3
36 mismatch repair cancer syndrome 11.2
37 ras-associated autoimmune leukoproliferative disorder 11.1
38 systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 11.1
39 medulloblastoma 11.0
40 anemia, sideroblastic, 1 11.0
41 surfactant metabolism dysfunction, pulmonary, 4 11.0
42 thrombocytopenia 5 11.0
43 sideroblastic anemia 11.0
44 paroxysmal cold hemoglobinuria 11.0
45 pulmonary alveolar proteinosis, acquired 10.9
46 lymphoma 10.9
47 central nervous system leukemia 10.9
48 central nervous system lymphoma 10.9
49 mast cell neoplasm 10.9
50 histiocytic and dendritic cell cancer 10.9

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer

Symptoms & Phenotypes for Hematologic Cancer

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 ABL1 CBL CSF2 ETV6 FLT3 IL2
2 growth/size/body region MP:0005378 10.39 ABL1 CBL CSF2 ENG ETV6 FLT3
3 hematopoietic system MP:0005397 10.37 ABL1 CBL CSF2 ENG ETV6 FLT3
4 homeostasis/metabolism MP:0005376 10.32 ABL1 CBL CSF2 ENG ETV6 FLT3
5 cardiovascular system MP:0005385 10.31 ABL1 CBL CSF2 ENG ETV6 IL2
6 immune system MP:0005387 10.3 ABL1 CBL CSF2 ETV6 FLT3 IL2
7 embryo MP:0005380 10.28 ABL1 CSF2 ENG ETV6 JAK2 KIT
8 endocrine/exocrine gland MP:0005379 10.26 ABL1 CBL CSF2 ETV6 FLT3 IL2
9 mortality/aging MP:0010768 10.24 ABL1 CBL CSF2 ENG ETV6 FLT3
10 craniofacial MP:0005382 10.09 ABL1 CBL CSF2 ENG KIT KMT2A
11 integument MP:0010771 10.09 CBL CSF2 ENG ETV6 JAK2 KIT
12 liver/biliary system MP:0005370 10.06 ABL1 CBL IL2 JAK2 KIT KMT2A
13 neoplasm MP:0002006 10.02 CSF2 ETV6 FLT3 IL2 JAK2 KIT
14 normal MP:0002873 9.81 ABL1 ENG ETV6 JAK2 KIT KMT2A
15 no phenotypic analysis MP:0003012 9.8 ETV6 FLT3 IL2 KIT KMT2A RUNX1
16 respiratory system MP:0005388 9.61 ABL1 CBL CSF2 ENG IL2 KIT
17 skeleton MP:0005390 9.28 ABL1 CBL CSF2 FLT3 JAK2 KIT

Drugs & Therapeutics for Hematologic Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
3
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 537)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
6
Protein C Approved Phase 4,Phase 2
7
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1 191732-72-6 216326
8
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 179324-69-7 387447 93860
9
Caspofungin Approved Phase 4,Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
10
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
11
Nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1 946414-94-4
12
Daratumumab Approved Phase 4,Phase 3,Phase 2,Phase 1 945721-28-8
13 Ixazomib Approved, Investigational Phase 4,Phase 2,Phase 1 1072833-77-2
14
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
15
Ofloxacin Approved Phase 4 82419-36-1 4583
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
26 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
34 Drotrecogin alfa activated Phase 4
35 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37
Hydroxyitraconazole Phase 4
38 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Echinocandins Phase 4,Phase 3,Phase 2
40 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Mitogens Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 2
45
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
46
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
47
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
48
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 302-25-0
49
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
50
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2921-57-5

Interventional clinical trials:

(show top 50) (show all 933)
# Name Status NCT ID Phase Drugs
1 A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM) Completed NCT02966457 Phase 4 Colistimethate Sodium
2 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Recruiting NCT03023631 Phase 4
5 An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Recruiting NCT02869789 Phase 4 Nivolumab in combination with Ipilimumab
6 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
7 A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Terminated NCT02895529 Phase 4 Itraconazole;Caspofungin
8 SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients Terminated NCT01222819 Phase 4 filgrastim
9 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
10 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
11 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
12 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
13 Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
14 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
15 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
16 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
18 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
19 Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Completed NCT01767467 Phase 3 Placebo
20 Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed NCT00044759 Phase 3 Piperacillin/Tazobactam (Tazocin)
21 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3
22 Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens Completed NCT02635984 Phase 3 Olanzapine;Placebo
23 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
24 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients Completed NCT00824993 Phase 3 Ibandronate;Vitamin Supplements
25 Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy Completed NCT01435200 Phase 3 Intravenous iron
26 Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01237639 Phase 3
27 A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Completed NCT00300664 Phase 2, Phase 3 Human Growth hormone
28 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
29 Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection Completed NCT01032408 Phase 3
30 INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant Completed NCT01602211 Phase 3
31 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed NCT00750737 Phase 3 Posaconazole;ABLC
32 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
33 A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients Completed NCT01769170 Phase 3 Brincidofovir (CMX001)
34 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
35 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients Completed NCT01568866 Phase 3 Carfilzomib;Bortezomib;Dexamethasone
36 Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT02229539 Phase 3 doxepin hydrochloride oral solution;DLA (diphenhydramine, lidocaine and antacids) rinse
37 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Completed NCT02116530 Phase 3 Olanzapine;Chemotherapy (cisplatin or cyclophosphamide and doxorubicin);Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
38 Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed NCT01080391 Phase 3 Dexamethasone;Lenalidomide;Carfilzomib
39 Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Completed NCT01109004 Phase 3 Lenalidomide;lenalidomide, bortezomib and dexamethasone;Lenalidomide
40 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed NCT00075829 Phase 3 Thalidomide;Dexamethasone
41 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
42 PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00048230 Phase 3 bortezomib
43 Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) Completed NCT01410227 Phase 3 Placebo
44 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
45 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Completed NCT02292446 Phase 3 Ruxolitinib
46 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
47 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
48 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
49 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Completed NCT01243944 Phase 3 ruxolitinib tablets
50 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib

Search NIH Clinical Center for Hematologic Cancer

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hematologic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hematologic Cancer:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord�, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx�, umbilical cord blood stem/progenitor cells for hematological diseases
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Hematologic Cancer:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Umbilical cord blood-derived hematopoietic progenitor cells (Allocord) PMIDs: 11953027
Peripheral blood-derived hematopoietic stem cells
Umbilical cord blood-derived hematopoietic progenitor cells (Ducord) PMIDs: 22698485 21810098 23711284 21277377
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 20676147

Cochrane evidence based reviews: hematologic neoplasms

Genetic Tests for Hematologic Cancer

Genetic tests related to Hematologic Cancer:

# Genetic test Affiliating Genes
1 Hematologic Neoplasm 29

Anatomical Context for Hematologic Cancer

MalaCards organs/tissues related to Hematologic Cancer:

41
Bone, Bone Marrow, T Cells, Lymph Node, Myeloid, B Cells, Prostate

Publications for Hematologic Cancer

Articles related to Hematologic Cancer:

(show top 50) (show all 54)
# Title Authors Year
1
Pre- and post-diagnosis physical activity, television viewing, and mortality among hematologic cancer survivors. ( 29385194 )
2018
2
Feasibility and preliminary efficacy of an exercise telephone counseling intervention for hematologic cancer survivors: a phase II randomized controlled trial. ( 29411314 )
2018
3
Factors influencing infection prevention self-care behaviors in patients with hematologic cancer after discharge. ( 30057076 )
2018
4
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. ( 30254093 )
2018
5
The Impact of Hematologic Cancer and Its Treatment on Physical Activity Level and Quality of Life Among Children in Mainland China: A Descriptive Study. ( 30433896 )
2018
6
Social Cognitive Effects and Mediators of a Pilot Telephone Counseling Intervention to Increase Aerobic Exercise in Hematologic Cancer Survivors. ( 30501541 )
2018
7
Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. ( 30156701 )
2018
8
Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): Uncommon, with improved survival but still deadly often. ( 28919347 )
2017
9
Psychological distress, chronic conditions and quality of life in elderly hematologic cancer patients: study protocol of a prospective study. ( 29070033 )
2017
10
Childhood hematologic cancer and residential proximity to oil and gas development. ( 28199334 )
2017
11
Body Image Discomfort of Adolescent and Young Adult Hematologic Cancer Survivors. ( 28112547 )
2017
12
Correlates of meeting the combined and independent aerobic and strength exercise guidelines in hematologic cancer survivors. ( 28351397 )
2017
13
Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. ( 28778967 )
2017
14
Living with hematologic cancer: Recommendations, solutions. ( 28696193 )
2017
15
Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners. ( 27987096 )
2017
16
Understanding strength exercise intentions and behavior in hematologic cancer survivors: an analysis of the intention-behavior gap. ( 27052642 )
2016
17
Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. ( 27400009 )
2016
18
Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? ( 27282880 )
2016
19
Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls. ( 26763882 )
2016
20
Survivorship Care Plans and Treatment Summaries a8"in Adult Patients With Hematologic Cancer: a8"An Integrative Literature Review. ( 25901380 )
2015
21
Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. ( 26310541 )
2015
22
Cancer Care Burden among Primary Family Caregivers of Iranian Hematologic Cancer Patients. ( 26225701 )
2015
23
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin for Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Saudi Arabia. ( 26533739 )
2015
24
Hospitalization risk according to geriatric assessment and laboratory parameters in elderly hematologic cancer patients. ( 25684525 )
2015
25
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B for Primary Therapy of Invasive Aspergillosis among High-Risk Hematologic Cancer Patients in Brazil. ( 26534377 )
2015
26
Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. ( 26628205 )
2015
27
The falling incidence of hematologic cancer after heart transplantation. ( 25100534 )
2014
28
The microfluidic multitrap nanophysiometer for hematologic cancer cell characterization reveals temporal sensitivity of the calcein-AM efflux assay. ( 24873950 )
2014
29
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. ( 24645687 )
2014
30
Anti-tumor activity and relative mechanism of ethanolic extract of Marsdenia tenacissima (Asclepiadaceae) against human hematologic neoplasm in vitro and in vivo. ( 24583069 )
2014
31
Internet-based program for coping with cancer: a randomized controlled trial with hematologic cancer patients. ( 22565413 )
2013
32
Confirmation of the reported association of clonal chromosomal mosaicism with an increased risk of incident hematologic cancer. ( 23533652 )
2013
33
Xist RNA is a potent suppressor of hematologic cancer in mice. ( 23415223 )
2013
34
Expression of ICOSLG on mouse hematologic neoplasm cell lines and their influence on cytotoxicity in allogeneic mixed lymphocyte reactions. ( 21958057 )
2012
35
Physical activity and hematologic cancer prevention. ( 21113763 )
2011
36
Improving access to information and support for patients with less common cancers: hematologic cancer patients' views about Web-based approaches. ( 22189354 )
2011
37
Evolving information priorities of hematologic cancer survivors, caregivers, and other relatives. ( 20119694 )
2010
38
Mesial temporal sclerosis as a complication of hematologic cancer. ( 19434437 )
2009
39
Managed care considerations: hematologic cancer as a chronic disease. ( 19119536 )
2008
40
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. ( 18344563 )
2008
41
Phase 3 trials suggest ways to improve current hematologic cancer therapies. ( 18252877 )
2008
42
Femoral resurfacing in young patients with hematologic cancer and osteonecrosis. ( 18679763 )
2008
43
Posaconazole prophylaxis in hematologic cancer. ( 17526089 )
2007
44
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. ( 17607669 )
2007
45
Posaconazole prophylaxis in hematologic cancer. ( 17526091 )
2007
46
Posaconazole prophylaxis in hematologic cancer. ( 17526090 )
2007
47
Posaconazole prophylaxis in hematologic cancer. ( 17522407 )
2007
48
Patient-rated emotional and physical functioning among hematologic cancer patients during hospitalization for stem-cell transplantation. ( 15580279 )
2005
49
Treatment of patients with hematologic neoplasm, fever, and neutropenia. ( 15768331 )
2005
50
Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. ( 11919251 )
2002

Variations for Hematologic Cancer

ClinVar genetic disease variations for Hematologic Cancer:

6 (show all 32)
# Gene Variation Type Significance SNP ID Assembly Location
1 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs267606706 GRCh37 Chromosome 11, 119148891: 119148891
2 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs267606706 GRCh38 Chromosome 11, 119278181: 119278181
3 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 GRCh37 Chromosome 4, 55599321: 55599321
4 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 GRCh38 Chromosome 4, 54733155: 54733155
5 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
6 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
7 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
8 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
9 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
10 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh38 Chromosome 4, 54728055: 54728055
11 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic rs121913615 GRCh37 Chromosome 1, 43815009: 43815009
12 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic rs121913615 GRCh38 Chromosome 1, 43349338: 43349338
13 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 GRCh37 Chromosome 11, 119148930: 119148930
14 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 GRCh38 Chromosome 11, 119278220: 119278220
15 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh38 Chromosome 12, 11869601: 11869601
16 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh37 Chromosome 12, 12022535: 12022535
17 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh38 Chromosome 12, 11884541: 11884541
18 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh37 Chromosome 12, 12037475: 12037475
19 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh37 Chromosome 12, 12038902: 12038902
20 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh38 Chromosome 12, 11885968: 11885968
21 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh37 Chromosome 5, 149441328: 149441328
22 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh38 Chromosome 5, 150061765: 150061765
23 CSF1R NM_005211.3(CSF1R): c.2906A> T (p.Tyr969Phe) single nucleotide variant Likely pathogenic rs1801271 GRCh37 Chromosome 5, 149433645: 149433645
24 CSF1R NM_005211.3(CSF1R): c.2906A> T (p.Tyr969Phe) single nucleotide variant Likely pathogenic rs1801271 GRCh38 Chromosome 5, 150054082: 150054082
25 CSF1R NM_005211.3(CSF1R): c.2906A> G (p.Tyr969Cys) single nucleotide variant Likely pathogenic rs1801271 GRCh37 Chromosome 5, 149433645: 149433645
26 CSF1R NM_005211.3(CSF1R): c.2906A> G (p.Tyr969Cys) single nucleotide variant Likely pathogenic rs1801271 GRCh38 Chromosome 5, 150054082: 150054082
27 CSF1R NM_005211.3(CSF1R): c.2905T> C (p.Tyr969His) single nucleotide variant Likely pathogenic rs121913393 GRCh37 Chromosome 5, 149433646: 149433646
28 CSF1R NM_005211.3(CSF1R): c.2905T> C (p.Tyr969His) single nucleotide variant Likely pathogenic rs121913393 GRCh38 Chromosome 5, 150054083: 150054083
29 CSF1R NM_005211.3(CSF1R): c.902T> C (p.Leu301Ser) single nucleotide variant Likely pathogenic rs121913390 GRCh37 Chromosome 5, 149453044: 149453044
30 CSF1R NM_005211.3(CSF1R): c.902T> C (p.Leu301Ser) single nucleotide variant Likely pathogenic rs121913390 GRCh38 Chromosome 5, 150073481: 150073481
31 CSF1R NM_005211.3(CSF1R): c.903G> T (p.Leu301Phe) single nucleotide variant Likely pathogenic rs1057520014 GRCh37 Chromosome 5, 149453043: 149453043
32 CSF1R NM_005211.3(CSF1R): c.903G> T (p.Leu301Phe) single nucleotide variant Likely pathogenic rs1057520014 GRCh38 Chromosome 5, 150073480: 150073480

Expression for Hematologic Cancer

Search GEO for disease gene expression data for Hematologic Cancer.

Pathways for Hematologic Cancer

Pathways related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 CBL CSF2 FLT3 IL2 IL3 JAK2
2
Show member pathways
12.69 ABL1 CBL CSF2 FLT3 IL3 KIT
3 12.48 ABL1 CBL FLT3 IL2 IL3 JAK2
4
Show member pathways
12.39 CBL CSF2 IL2 IL3
5 12.32 CBL IL2 IL3 JAK2 KIT MPL
6
Show member pathways
12.27 CBL FLT3 IL2 IL3 KIT
7
Show member pathways
12.2 CBL FLT3 IL3 JAK2
8
Show member pathways
12.16 ABL1 CSF2 IL2 IL3 JAK2 MPL
9
Show member pathways
12.04 CBL IL3 JAK2 KIT
10
Show member pathways
12.01 CSF2 IL2 IL3 JAK2
11 11.94 ABL1 CBL FLT3 JAK2 KIT
12 11.77 CSF2 ETV6 FLT3 IL3 KMT2A RUNX1
13 11.74 ABL1 IL2 IL3 JAK2
14 11.74 CSF2 FLT3 IL3 KIT
15 11.67 IL2 KIT RUNX1
16
Show member pathways
11.64 CSF2 IL2 IL3
17 11.6 CSF2 FLT3 IL2 KIT
18 11.55 ABL1 IL2 WT1
19 11.4 CSF2 IL3 RUNX1
20 11.23 CSF2 ENG FLT3 IL2 IL3 KIT
21 11.12 CSF2 IL2 IL3
22 10.9 CSF2 FLT3 IL2 IL3 KIT
23 10.81 CBL KIT

GO Terms for Hematologic Cancer

Biological processes related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.87 CSF2 FLT3 IL2 IL3 JAK2 KIT
2 male gonad development GO:0008584 9.8 CBL KIT WT1
3 protein autophosphorylation GO:0046777 9.76 ABL1 FLT3 JAK2 KIT
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.75 ABL1 IL3 JAK2
5 MAPK cascade GO:0000165 9.73 CSF2 FLT3 IL2 IL3 JAK2 KIT
6 hemopoiesis GO:0030097 9.72 FLT3 KIT RUNX1
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 CBL FLT3 JAK2 KIT
8 peptidyl-tyrosine phosphorylation GO:0018108 9.63 ABL1 CSF2 FLT3 IL3 JAK2 KIT
9 regulation of regulatory T cell differentiation GO:0045589 9.62 IL2 RUNX1
10 interleukin-6-mediated signaling pathway GO:0070102 9.61 CBL JAK2
11 regulation of hematopoietic stem cell differentiation GO:1902036 9.61 ABL1 KMT2A RUNX1
12 negative regulation of cell-cell adhesion GO:0022408 9.6 ABL1 JAK2
13 mast cell degranulation GO:0043303 9.59 CBL KIT
14 hematopoietic stem cell proliferation GO:0071425 9.58 ETV6 RUNX1
15 dendritic cell differentiation GO:0097028 9.57 CSF2 FLT3
16 regulation of myeloid cell differentiation GO:0045637 9.56 CSF2 RUNX1
17 cytokine-mediated signaling pathway GO:0019221 9.56 CBL CSF2 FLT3 IL2 IL3 JAK2
18 negative regulation of heart contraction GO:0045822 9.54 IL2 JAK2
19 embryonic hemopoiesis GO:0035162 9.54 IL3 KIT KMT2A
20 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.52 ENG KIT
21 regulation of cytokine-mediated signaling pathway GO:0001959 9.51 IL3 RUNX1
22 myeloid progenitor cell differentiation GO:0002318 9.48 FLT3 KIT
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.1 CSF2 FLT3 IL2 IL3 JAK2 KIT
24 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 ENG ETV6 IL2 KMT2A MLLT10 RUNX1
25 negative regulation of apoptotic process GO:0043066 10.01 CBL FLT3 IL2 KIT WT1

Molecular functions related to Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.8 CBL ETV6 KMT2A MLLT10 RUNX1 WT1
2 transmembrane signaling receptor activity GO:0004888 9.46 ENG FLT3 KIT MPL
3 protein tyrosine kinase activity GO:0004713 9.43 ABL1 CSF2 FLT3 IL3 JAK2 KIT
4 peptide hormone receptor binding GO:0051428 9.26 JAK2 PTHLH
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.1 CSF2 FLT3 IL2 IL3 JAK2 KIT

Sources for Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....